These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 28405610)

  • 1. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN
    Katewa A; Wang Y; Hackney JA; Huang T; Suto E; Ramamoorthi N; Austin CD; Bremer M; Chen JZ; Crawford JJ; Currie KS; Blomgren P; DeVoss J; DiPaolo JA; Hau J; Johnson A; Lesch J; DeForge LE; Lin Z; Liimatta M; Lubach JW; McVay S; Modrusan Z; Nguyen A; Poon C; Wang J; Liu L; Lee WP; Wong H; Young WB; Townsend MJ; Reif K
    JCI Insight; 2017 Apr; 2(7):e90111. PubMed ID: 28405610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
    Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
    Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.
    Rankin AL; Seth N; Keegan S; Andreyeva T; Cook TA; Edmonds J; Mathialagan N; Benson MJ; Syed J; Zhan Y; Benoit SE; Miyashiro JS; Wood N; Mohan S; Peeva E; Ramaiah SK; Messing D; Homer BL; Dunussi-Joannopoulos K; Nickerson-Nutter CL; Schnute ME; Douhan J
    J Immunol; 2013 Nov; 191(9):4540-50. PubMed ID: 24068666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
    Chalmers SA; Wen J; Doerner J; Stock A; Cuda CM; Makinde HM; Perlman H; Bosanac T; Webb D; Nabozny G; Fine JS; Klein E; Ramanujam M; Putterman C
    Arthritis Res Ther; 2018 Jan; 20(1):10. PubMed ID: 29370834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.
    Mina-Osorio P; LaStant J; Keirstead N; Whittard T; Ayala J; Stefanova S; Garrido R; Dimaano N; Hilton H; Giron M; Lau KY; Hang J; Postelnek J; Kim Y; Min S; Patel A; Woods J; Ramanujam M; DeMartino J; Narula S; Xu D
    Arthritis Rheum; 2013 Sep; 65(9):2380-91. PubMed ID: 23754328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice.
    Sitrin J; Suto E; Wuster A; Eastham-Anderson J; Kim JM; Austin CD; Lee WP; Behrens TW
    J Immunol; 2017 Aug; 199(4):1238-1249. PubMed ID: 28696253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BTK inhibition modulates multiple immune cell populations involved in the pathogenesis of immune mediated nephritis.
    Chalmers SA; Garcia SJ; Webb D; Herlitz L; Fine J; Klein E; Ramanujam M; Putterman C
    Clin Immunol; 2021 Feb; 223():108640. PubMed ID: 33296718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.
    Kim YY; Park KT; Jang SY; Lee KH; Byun JY; Suh KH; Lee YM; Kim YH; Hwang KW
    Arthritis Res Ther; 2017 Sep; 19(1):211. PubMed ID: 28950886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of Bruton's tyrosine kinase in peripheral blood is associated with lupus nephritis.
    Kong W; Deng W; Sun Y; Huang S; Zhang Z; Shi B; Chen W; Tang X; Yao G; Feng X; Sun L
    Clin Rheumatol; 2018 Jan; 37(1):43-49. PubMed ID: 28612243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR1 inhibition ameliorates the progression of lupus nephritis in NZB/W mice.
    Bignon A; Gaudin F; Hémon P; Tharinger H; Mayol K; Walzer T; Loetscher P; Peuchmaur M; Berrebi D; Balabanian K
    J Immunol; 2014 Feb; 192(3):886-96. PubMed ID: 24367031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
    Haselmayer P; Camps M; Liu-Bujalski L; Nguyen N; Morandi F; Head J; O'Mahony A; Zimmerli SC; Bruns L; Bender AT; Schroeder P; Grenningloh R
    J Immunol; 2019 May; 202(10):2888-2906. PubMed ID: 30988116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus.
    Brightbill HD; Suto E; Blaquiere N; Ramamoorthi N; Sujatha-Bhaskar S; Gogol EB; Castanedo GM; Jackson BT; Kwon YC; Haller S; Lesch J; Bents K; Everett C; Kohli PB; Linge S; Christian L; Barrett K; Jaochico A; Berezhkovskiy LM; Fan PW; Modrusan Z; Veliz K; Townsend MJ; DeVoss J; Johnson AR; Godemann R; Lee WP; Austin CD; McKenzie BS; Hackney JA; Crawford JJ; Staben ST; Alaoui Ismaili MH; Wu LC; Ghilardi N
    Nat Commun; 2018 Jan; 9(1):179. PubMed ID: 29330524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.
    Lourenço EV; Wong M; Hahn BH; Palma-Diaz MF; Skaggs BJ
    Arthritis Rheumatol; 2014 Mar; 66(3):674-85. PubMed ID: 24574228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice.
    Jacob N; Guo S; Mathian A; Koss MN; Gindea S; Putterman C; Jacob CO; Stohl W
    J Immunol; 2011 Apr; 186(8):4984-93. PubMed ID: 21383240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis.
    Liao W; Zheng H; Wu S; Zhang Y; Wang W; Zhang Z; Zhou C; Wu H; Min J
    Am J Nephrol; 2017; 46(5):371-379. PubMed ID: 29069649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus.
    Hutcheson J; Vanarsa K; Bashmakov A; Grewal S; Sajitharan D; Chang BY; Buggy JJ; Zhou XJ; Du Y; Satterthwaite AB; Mohan C
    Arthritis Res Ther; 2012 Nov; 14(6):R243. PubMed ID: 23136880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies from long-lived 'memory' plasma cells of NZB/W mice drive immune complex nephritis.
    Cheng Q; Mumtaz IM; Khodadadi L; Radbruch A; Hoyer BF; Hiepe F
    Ann Rheum Dis; 2013 Dec; 72(12):2011-7. PubMed ID: 24114925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleosomes contribute to increase mesangial cell chemokine expression during the development of lupus nephritis.
    Kanapathippillai P; Hedberg A; Fenton CG; Fenton KA
    Cytokine; 2013 May; 62(2):244-52. PubMed ID: 23561928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antroquinonol differentially modulates T cell activity and reduces interleukin-18 production, but enhances Nrf2 activation, in murine accelerated severe lupus nephritis.
    Tsai PY; Ka SM; Chang JM; Lai JH; Dai MS; Jheng HL; Kuo MT; Chen P; Chen A
    Arthritis Rheum; 2012 Jan; 64(1):232-42. PubMed ID: 21905011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus.
    Lin W; Seshasayee D; Lee WP; Caplazi P; McVay S; Suto E; Nguyen A; Lin Z; Sun Y; DeForge L; Balazs M; Martin F; Zarrin AA
    Arthritis Rheumatol; 2015 Jan; 67(1):215-24. PubMed ID: 25303150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.